ARTICLE | Clinical News
BBG's E21R starts Phase II
March 6, 2001 8:00 AM UTC
British Biotech (LSE:BBG; BBIOY) said that partner BresaGen (ASX:BGN) began an Australian Phase II trial of BBG's E21R modified GM-CSF to treat chronic myelomonocytic leukemia. ...